Medincell (STU:MEB) Capex-to-Operating-Income : 0.00 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Medincell Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Medincell's Capital Expenditure for the six months ended in Sep. 2023 was €-0.39 Mil. Its Operating Income for the six months ended in Sep. 2023 was €-8.98 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Medincell Capex-to-Operating-Income Historical Data

The historical data trend for Medincell's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Capex-to-Operating-Income Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Capex-to-Operating-Income

Get a 7-Day Free Trial

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Capex-to-Operating-Income	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Medincell's Capex-to-Operating-Income

For the Biotechnology subindustry, Medincell's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medincell's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Medincell's Capex-to-Operating-Income falls into.

Medincell Capex-to-Operating-Income Calculation

Medincell's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-1.027)	/	-24.045
	=	N/A

Medincell's Capex-to-Operating-Income for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.387)	/	-8.982
	=	N/A

Medincell (STU:MEB) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Medincell Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Medincell's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (STU:MEB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (STU:MEB) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

MEDCL:France MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (STU:MEB) Headlines

No Headlines